Self-Pay Ketamine Treatments

Patients considering off-label treatments, such as intravenous (IV), intramuscular (IM), or sublingual ketamine, should anticipate these services to be primarily self-pay. Because these specific formulations are not FDA-approved for mental health conditions, health insurance plans typically do not cover the cost of the drug or the medical observation time required. It is advisable to request a written estimate from the clinic that outlines the total cost of the initial treatment series and any maintenance sessions. Patients should also familiarize themselves with the FDA warning on compounded ketamine to understand the potential risks.

Spravato Insurance Considerations

Spravato (esketamine) is an FDA-approved nasal spray indicated for specific adult depression diagnoses, such as treatment-resistant depression. Unlike off-label ketamine infusions, Spravato is more likely to be eligible for insurance coverage, though plans and benefits vary widely. Prior authorization is generally mandatory, and patients must meet strict clinical criteria. Even when the medication is covered, patients may still be responsible for copayments related to the clinic visit and the mandatory observation period. Never assume full coverage; always verify benefits with your insurer and the treating clinic directly.

Planning Your Treatment Schedule

Committing to ketamine therapy involves a comprehensive initial assessment, followed by a series of closely spaced treatment sessions. While having local care in Flagstaff simplifies logistics, patients who choose to travel to Phoenix must account for the two-hour drive along I-17. Winter snowstorms in Coconino County or intense summer heat in the valley can complicate travel plans, so reliable transportation is critical.

Telehealth may be used for assessments or follow-up, but it does not establish that a clinic offers home treatment. Spravato must be administered in a certified healthcare setting with at least two hours of observation. Some clinicians prescribe other ketamine formulations off-label for home use; those products are not FDA-approved for psychiatric treatment, and the FDA warns about compounded ketamine risks, especially without on-site monitoring. Confirm the formulation, setting and safety plan with the prescriber; never assume infusion or Spravato services are offered remotely.

Safety and Observation Protocols

If you receive Spravato, the FDA requires it to be administered in a certified healthcare facility. After receiving the medication, patients must undergo at least two hours of medical observation to monitor for potential side effects, including dissociation or sedation. Because these effects can impair coordination, patients cannot drive or operate machinery until the next day, following a restful sleep. A responsible adult must be present to drive you home after every session. For immediate mental health support, contact the Arizona statewide crisis line at 1-844-534-4673 or dial 988 anytime.